bromodeoxyuridine has been researched along with Bone Cancer in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Hooper, JD; Kularathna, PK; Mackie, EJ; Pagel, CN; Sanaei, R; Young, ND | 1 |
| Bohr, VA; Christmann, M; Gestrich, C; Kaina, B; Roos, WP; Tomicic, MT | 1 |
| Emond, MJ; Lauper, JM; Mao, FJ; Monnat, RJ; Sidorova, JM | 1 |
| Johansson, M; Karlsson, A; Lundberg, M; Zheng, X | 1 |
| Jabri, M; Lejeune, FJ; Nogaret, JM; Regnier, R | 1 |
| Hong, SH; Kadosawa, T; Matsunaga, S; Mochizuki, M; Nishimura, R; Nozaki, K; Sasaki, N | 1 |
| Baldini, N; Benini, S; Cerisano, V; Lollini, PL; Manara, MC; Mercuri, M; Nanni, P; Picci, P; Scotlandi, K | 1 |
| Pawelek, JM | 1 |
| Harada, M; Nakamura, Y; Nemoto, R; Shimizu, A | 1 |
| Glatstein, E; Kinsella, TJ | 1 |
| Bagshaw, MA; Donaldson, SS; Goffinet, DR; Kaplan, HS; Martinez, A | 1 |
1 review(s) available for bromodeoxyuridine and Bone Cancer
| Article | Year |
|---|---|
Factors regulating growth and pigmentation of melanoma cells.
Topics: Animals; Bone Neoplasms; Bromodeoxyuridine; Catechol Oxidase; Cell Division; Cell Line; Cell Transformation, Neoplastic; Cricetinae; Cyclic AMP; Dihydroxyphenylalanine; Melanins; Melanocyte-Stimulating Hormones; Melanocytes; Melanoma; Mice; Neoplasms, Experimental; Oncogenic Viruses; Pigmentation; Tyrosine | 1976 |
10 other study(ies) available for bromodeoxyuridine and Bone Cancer
| Article | Year |
|---|---|
Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
Topics: Alkaline Phosphatase; Animals; Bone Neoplasms; Bromodeoxyuridine; Cell Differentiation; Cell Line, Tumor; Humans; Male; Mice; Osteoblasts; Osteoclasts; Prostatic Neoplasms; Receptor, PAR-2; Receptors, Proteinase-Activated | 2022 |
WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Neoplasms; Bromodeoxyuridine; Cell Cycle; Cell Survival; Colony-Forming Units Assay; DNA Breaks; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Exodeoxyribonucleases; Histones; Humans; Osteosarcoma; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Werner Syndrome Helicase | 2008 |
The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage.
Topics: Antineoplastic Agents; Bone Neoplasms; Bromodeoxyuridine; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Cisplatin; DNA Damage; Exodeoxyribonucleases; Fibroblasts; Fluorouracil; Histones; Humans; Hydroxyurea; Osteosarcoma; RecQ Helicases; Werner Syndrome Helicase | 2010 |
Lipid-mediated protein delivery of suicide nucleoside kinases.
Topics: Animals; Arabinonucleosides; Bone Neoplasms; Bromodeoxyuridine; Cell Line, Tumor; CHO Cells; Cricetinae; Drosophila melanogaster; Endocytosis; Ganciclovir; Herpesvirus 1, Human; Humans; Liposomes; Osteosarcoma; Phosphatidylethanolamines; Phosphotransferases (Alcohol Group Acceptor); Recombinant Proteins; Thymidine; Thymidine Kinase | 2003 |
Intra-arterial infusion of bromodeoxyuridine and radiotherapy in osteosarcoma and other bone malignancies.
Topics: Bone Neoplasms; Bromodeoxyuridine; Combined Modality Therapy; Humans; Infusions, Intra-Arterial; Osteosarcoma; Soft Tissue Neoplasms | 1983 |
In vitro retinoid-induced growth inhibition and morphologic differentiation of canine osteosarcoma cells.
Topics: Alitretinoin; Animals; Antimetabolites; Antineoplastic Agents; Bone Neoplasms; Bromodeoxyuridine; Cell Division; DNA; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Microscopy, Phase-Contrast; Osteosarcoma; Tretinoin; Tumor Cells, Cultured | 2000 |
Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Bromodeoxyuridine; Cell Cycle; Cell Division; Cell Nucleus; Dose-Response Relationship, Drug; Doxorubicin; Humans; Receptor, IGF Type 1; Sarcoma, Ewing; Suramin; Tumor Cells, Cultured; Vincristine | 2001 |
Role of the vertebral venous system in metastatic spread of cancer cells to the bone.
Topics: Adenocarcinoma; Animals; Bone Marrow; Bone Neoplasms; Bromodeoxyuridine; Constriction; Epidural Space; Humans; Incidence; Lung; Male; Mice; Mice, Inbred C3H; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Osteosarcoma; Prostatic Neoplasms; Spine; Tail; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured; Veins; Vena Cava, Inferior | 1992 |
Clinical experience with intravenous radiosensitizers in unresectable sarcomas.
Topics: Adolescent; Adult; Aged; Bone and Bones; Bone Neoplasms; Bromodeoxyuridine; Female; Humans; Injections, Intravenous; Male; Middle Aged; Misonidazole; Radiation Dosage; Radiation-Sensitizing Agents; Sarcoma | 1987 |
Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bromodeoxyuridine; Child; Child, Preschool; Combined Modality Therapy; Follow-Up Studies; Hand Dermatoses; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Osteosarcoma; Pubic Bone; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1985 |